The drug baricitinib is strongly recommended for patients with severe or critical Covid-19, in combination with corticosteroids, said a World Health Organization (WHO) Guideline Development Group of international experts in The BMJ medical journal on Jan 13 (2022).
Their strong recommendation is based on evidence of moderate certainty that it improves survival and reduces the need for ventilation, with no observed increase in adverse effects.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!